Trend Reports
The CFSRE is developing quarterly trend reports associated with NPS occurrence in the United States. These trend reports are intended to provide near real-time information regarding NPS prevalence, positivity, and turnover. Testing was performed using toxicology samples and drug materials. The CFSRE receives funding from the National Institute of Justice (NIJ) of the Department of Justice (DOJ) to continue development of this initiative. For more information regarding our trend reports, contact our scientists via This email address is being protected from spambots. You need JavaScript enabled to view it..
Trend Reports:
DOWNLOAD Q3 2024 NPS DISCOVERY TREND REPORTS
Year In Review:
Since 2018, NPS Discovery has reported 154 newly discovered NPS in the United States (Figure 1). NPS opioids remain the largest subclass (Figure 2). In 2023, NPS Discovery reported the discovery of 17 NPS for the first time.
Since 2018, NPS Discovery has identified 240 NPS in forensic samples (Figure 3). NPS opioids, stimulants, and cannabinoids represent the largest subclasses observed. In 2023, 79 total NPS were detected (Figure 4).
In 2023, NPS Discovery observed more than 3,600 total NPS detections within examined sample populations (Figure 5), a portion of more than 15,000 total NPS detections since our program launched in 2018 (Figure 6).
DOWNLOAD THE 2023 YEAR IN REVIEW
Since 2018, NPS Discovery has identified 240 NPS in forensic samples (Figure 3). NPS opioids, stimulants, and cannabinoids represent the largest subclasses observed. In 2023, 79 total NPS were detected (Figure 4).
In 2023, NPS Discovery observed more than 3,600 total NPS detections within examined sample populations (Figure 5), a portion of more than 15,000 total NPS detections since our program launched in 2018 (Figure 6).
Since 2018, NPS Discovery has reported 137 newly discovered NPS in the United States (Figure 1). NPS opioids remain the largest subclass (Figure 2). In 2022, NPS Discovery reported the discovery of 21 NPS for the first time.
Since 2018, NPS Discovery has identified 218 NPS in forensic samples (Figure 3). NPS opioids, stimulants, and cannabinoids represent the largest subclasses observed. In 2022, 76 total NPS were detected (Figure 4).
In 2022, NPS Discovery observed more than 2,200 total NPS detections within examined sample populations (Figure 5), a portion of more than 10,000 total NPS detections since our program launched in 2018 (Figure 6).
DOWNLOAD THE 2022 YEAR IN REVIEW
Since 2018, NPS Discovery has identified 218 NPS in forensic samples (Figure 3). NPS opioids, stimulants, and cannabinoids represent the largest subclasses observed. In 2022, 76 total NPS were detected (Figure 4).
In 2022, NPS Discovery observed more than 2,200 total NPS detections within examined sample populations (Figure 5), a portion of more than 10,000 total NPS detections since our program launched in 2018 (Figure 6).
Since 2018, NPS Discovery has reported 116 newly discovered NPS in the United States (Figure 1). NPS opioids remain the largest subclass (Figure 2). In 2021, NPS Discovery reported the discovery of 27 NPS for the first time.
Since 2018, NPS Discovery has identified 197 NPS in forensic samples (Figure 3). NPS opioids, stimulants, and cannabinoids represent the largest subclasses observed. In 2021, 97 total NPS were detected (Figure 4).
In 2021, NPS Discovery observed more than 2700 total NPS detections within examined sample populations (Figure 5), a portion of more than 8100 total NPS detections since our program launched in 2018 (Figure 6).
DOWNLOAD THE 2021 YEAR IN REVIEW